Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. Companies
  3. solid tumour
Show results for
Products
Services

Companies


Refine by
Locations

  • USA
  • Canada
  • Europe

  • Africa
  • Asia & Middle East
  • Australasia
  • Latin America
  • North America
Business Types

  • technology
Industries served

  • Medical / Health Care

Solid Tumour Suppliers & Manufacturers

10 companies found

Chimeric Therapeutics

Chimeric Therapeutics

Technologybased inCarlton South, AUSTRALIA
Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer not just delay disease ...
Chimeric - Model CHM 2101 (CDH17 CAR T) - T Cells for Derived Autologous Therapies

Chimeric - Model CHM 2101 (CDH17 CAR T) - T Cells for Derived Autologous Therapies

CHM 2101 (CDH17 CAR T) is an optimized 3rd generation CAR T cell therapy that is the first to target ...
CONTACT SUPPLIER

Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc.

Technologybased inNew York, NEW YORK (USA)
Stemline Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. The goal of our dedicated team of scientists, specialists, researchers, and developers is to build ...
Stemline - Model XPO1 - Regulate Nuclear Export

Stemline - Model XPO1 - Regulate Nuclear Export

XPO1 has been shown to regulate nuclear export of many of the major tumor suppressor proteins and oncogenic cell growth regulators. Overexpression of XPO1 has been reported in many cancer types and is associated with aggressive tumor behavior and ...
CONTACT SUPPLIER

NeoTherma Oncology

NeoTherma Oncology

Technologybased inWichita, KANSAS (USA)
Neotherma Oncology is led by experienced healthcare executives who are working toward the dream of more effective treatments for cancer. NeoTherma Oncology is developing a groundbreaking type of radio frequency (RF) thermal treatment for deep solid ...
NeoTherma VectRx - Clinical Stage Medical Device

NeoTherma VectRx - Clinical Stage Medical Device

NeoTherma Oncology is a clinical stage medical device company developing a proprietary Thermal Treatment (VectRx) system for deep solid tumors. Our technology is based on applying a safe, non-invasive, non-ionizing electromagnetic field to produce ...
CONTACT SUPPLIER

LIXTE Biotechnology Holdings, Inc.

LIXTE Biotechnology Holdings, Inc.

Technologybased inPasadena, CALIFORNIA (USA)
LIXTE is a drug discovery company that has a developed unique, proprietary, first in-class protein phosphatase inhibitor, LB-100, our lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in ...
Model LB-100 - Hematologic and Solid Tumor Cancers

Model LB-100 - Hematologic and Solid Tumor Cancers

Pre-clinical studies showed that LB-100 alone inhibits a spectrum of human cancers but when combined with standard cytotoxic drugs and/or radiation, LB-100 potentiates their effectiveness against hematologic and solid tumor cancers without enhancing ...
CONTACT SUPPLIER

AdAlta Limited

AdAlta Limited

Technologybased inBundoora, AUSTRALIA
AdAlta is an innovative, clinical stage biotech company developing a unique range of new drug treatments. AdAlta has pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, discovered initially in sharks and ...
AdAlta and Carina Biotech - i-body Enabled CAR-T Cancer Therapeutics

AdAlta and Carina Biotech - i-body Enabled CAR-T Cancer Therapeutics

AdAlta has entered a collaboration agreement with Carina Biotech to develop next-generation i-body enabled CAR-T cells, with the potential to bring CAR-T cell therapy to treat a far greater range of cancers than the small number of blood cancers ...
CONTACT SUPPLIER

AbelZeta Inc.

AbelZeta Inc.

Technologybased inRockville, MARYLAND (USA)
Since the treatment of our first oncology patient in 2015, AbelZeta has been able to build best-in-class and best-in-disease potential pipeline, leading to the licensing of two CD20-directed autologous CAR-Ts to Janssen Biotech in 2023. Our goal is ...
Model C-CAR031 - Solid Tumors

Model C-CAR031 - Solid Tumors

PRODUCT: C-CAR031. INDICATION: HCC. PLATFORM: CAR-T. PRECLINICAL: GPC3. IIT: -. PHASE 1/1B: -. PHASE 2: -. PARTNERS: ...
CONTACT SUPPLIER

Celluris

Celluris

Technologybased inSão Paulo, BRAZIL
Celluris is the first company in Latin America to develop personalized treatment for cancer patients through CAR-T immunotherapy. This technique is based on the modification of the patient’s own cells into recognizing the tumor as a target, fighting ...
Model CAR-T - Chimeric T Cell Antigen Receptor Therapy

Model CAR-T - Chimeric T Cell Antigen Receptor Therapy

The chimeric T cell antigen receptor therapy, also known as CAR-T, is an immunotherapy that is innovating the treatment of hematological and solid tumors. This new technology is considered less aggressive than conventional treatments, since it ...
CONTACT SUPPLIER

Myeloid Therapeutics

Myeloid Therapeutics

Technologybased inCambridge, MASSACHUSETTS (USA)
Myeloid Therapeutics is a leader in the development of mRNA-based immunotherapies, focusing on harnessing and enhancing the natural capabilities of myeloid cells to combat cancer. The company's cutting-edge in vivo engineering platform is designed ...
mRNA Cell Therapy Technology

mRNA Cell Therapy Technology

Myeloid is focused on advancing its ATAK CAR monocytes, which are myeloid cells with innate immune receptor-inspired CARs to recognize and kill cancer. Additionally, Myeloid has streamlined manufacturing for its ATAK cell therapy candidates through ...
CONTACT SUPPLIER

Sutro Biopharma Inc.

Sutro Biopharma Inc.

Technologybased inSouth San Francisco, CALIFORNIA (USA)
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next-generation cancer therapeutics – antibody drug conjugates, bispecific ...
CONTACT SUPPLIER

T3 Pharmaceuticals AG

T3 Pharmaceuticals AG

Technologybased inBasel, SWITZERLAND
T3 Pharmaceuticals was founded in May 2015 by Simon Ittig, Christoph Kasper, Marlise Amstutz and Helmut Kessmann as a spin-off of the University of Basel. The team has developed an efficient protein delivery technology that is based on the use of ...
Proprietary Platform for Protein Delivery

Proprietary Platform for Protein Delivery

T3 Pharma has developed a proprietary cancer therapy platform based on regulating and harnessing the natural behaviours of live bacteria. The genetically engineered bacteria selectively target solid tumors, where they deliver chosen protein payloads ...
CONTACT SUPPLIER
  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT